JOURNAL ARTICLE

Kiran Musunuru and Rebecca Ahrens-Nicklas.

  • Published In: TIME Magazine, 2026, v. 207, n. 13/14. P. 32 1 of 3

  • Database: Academic Search Ultimate 2 of 3

  • Authored By: Doudna, Jennifer 3 of 3

Abstract

The article focuses on the pioneering work of doctors Kiran Musunuru and Rebecca Ahrens-Nicklas in developing a personalized CRISPR genome-editing therapy to treat a rare metabolic disease in an infant named KJ. Their multi-institutional team designed, tested, and administered the treatment within six months, demonstrating that on-demand CRISPR therapies can be delivered safely and rapidly to patients in urgent need. This breakthrough represents a significant advancement in personalized genetic medicine, potentially benefiting thousands of children in the future. The article also references Jennifer Doudna, a Nobel Prize–winning biochemist and founder of the Innovative Genomics Institute, highlighting the broader context of CRISPR innovation. [Extracted from the article]

Additional Information

  • Source:TIME Magazine. 2026/04, Vol. 207, Issue 13/14, p32
  • Document Type:Article
  • Subject Area:Biology
  • Publication Date:2026
  • ISSN:0040-781X
  • Accession Number:193034741
  • Copyright Statement:Copyright of TIME Magazine is the property of TIME USA, LLC and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.